Component

MedimetRx [behavioral health screening] psychometrics

Validated behavioral health instruments, delivered and scored electronically, compared against normative data and against the person’s own previous results.

Why this exists

MedimetRx icon: an orange profile of a human head containing a three-bar chart

The co-occurrence of chronic pain with depression, post-traumatic stress and substance use disorder is well documented, and the federal Pain Management Best Practices Inter-Agency Task Force put a biopsychosocial model and a multidisciplinary approach at the head of its recommendations for exactly that reason. Psychosocial distress contributes to pain intensity, to pain-related disability and to poor response to treatment. Untreated psychiatric conditions raise the risk of medication mismanagement and overdose.

The practical problem is that this screening is recommended far more often than it is done, because doing it properly consumes clinical time that a pain visit does not have. The result is that the behavioral half of a biopsychosocial model quietly does not happen.

The specific thing worth catching early is suicidality. It is the outcome for which delay is least recoverable, and it is the one a rushed visit is most likely to miss.

How it works

  • The ordering clinician selects the instruments after an initial treatment plan exists. This is not a fixed battery applied to everyone.
  • The patient is invited by email and completes the screening in their own time, which produces better answers than a clipboard in a waiting room.
  • Scored against normative data and against the person’s own prior results, so that a change is visible rather than only an absolute score.
  • Critical results are highlighted for immediate clinical attention rather than appearing in a monthly summary.
  • Trends inform the treatment plan, and rescreening is guided by the plan and the clinical picture rather than by a fixed calendar.

What this is not

It is not a test anyone passes or fails. A screening instrument identifies who may benefit from further assessment. It is not a diagnosis and it is not a judgment.

It is not a risk score used to restrict access to treatment. A patient who screens positive for depression needs more support, not less medication and less contact. Any deployment in which a screening result triggered a restriction would be using this against its purpose, and the federal recommendations it is built on say the opposite.

It is not reported to an agency at the individual level. What an agency sees is whether screening is happening and what it finds in aggregate.

It is not a substitute for a clinician. Every critical result goes to a person.

A limitation worth stating: screening instruments have known limits in detecting existing or developing substance use disorder, and the federal Task Force material this component is built on says so directly. A negative screen is not a clearance.

Sources

Every figure on this page is traceable to the source listed here.

  • National Academies of Sciences, Engineering, and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Bonnie RJ, Ford MA, Phillips JK, editors. Washington, DC: The National Academies Press; 2017. View source.
  • Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95. PMID 36327391. View source.